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Purpose: Early thrombosis of infrainguinal bypass grafts may occur as a result of hyper- 
coagulable states. Major surgical procedures are known to induce a procoagulant s ate 
that is manifested in part by reduced endogenous fibrinolytic activity or fibrinolytic 
shutdown. This study was performed to assess the timing and biologic mechanism of 
fibrinolytic shutdown after infrainguinal bypass procedures by direct assay of the sero- 
logic markers of in vivo fibrinolytic activity. 
Methods: Twenty patients underwent infrainguiual bypass procedures under epidural 
anesthesia. Endogenous fibrinolytic activity was assessed by measurement of tissue 
plasminogen activator (tPA) and its naturally occurring inhibitor, plasminogen activator 
inhibitor (PAI-1). The tPA and PAI-1 antigen (total protein) levels were determined 
using enzyme-linked immunosorbent assays, and measurements of in vivo biologic 
activity were performed using an amidolytic method. Measurements of tPA and PAI-1 
were made before surgery, after surgery, and on postoperative days 1, 2, 7, and 30. 
Results: The mean preoperative PAI-1 activity was 20.6 _+ 1.4 arbitrary units (AU)/ml, 
which was higher than that of an age-matched population without severe atherosderosis. 
PAI-1 activity rose significantly after surgery (29.6 _ 2.2 AU/ml; p = 0.002) and 
remained elevated through the second day after surgery. Preoperative tPA activity level 
was 2.04 -+ 0.59 IU/ml and fell to 0.79 _ 0.23 IU/ml  (p = 0.046) immediately after the 
bypass procedure. All serologic indicators of fibrinolytic shutdown returned to baseline 
levels by 72 hours after surgery. No early graft thrombosis or other atherothrombotic 
complications occurred in these study patients. 
Conclusions: Defective ndogenous fibrinolytic activity occurs in the early postoperative 
period after infrainguinal bypass grafting procedures. Diminished endogenous fibrino- 
lyric activity in these patients appears to be mediated by a combination of reduced tPA 
activity and significantly increased PAI-1 activity. No practical method is available to 
directly treat postoperative fibrinolytic shutdown, but postoperative antithrombotic 
therapy may be useful during this period to prevent early graft occlusion related to a 
relative hypercoagulable state. (J Vasc Surg 1997;25:858-65.) 
Inffalnguinal bypass grafting procedures are per- 
formed most often for limb salvage indications, and 
early graft thrombosis may produce a worsening of 
ischemia and imminent limb jeopardy. Early graft 
failure (in the first 30 days) after inftainguinal bypass 
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grafting procedures has been reported in 4% to 10% 
of cases) 7 Early thrombosis of infrainguinal grafts 
has most often been attributed to technical problems 
but also may be a result of inadequate arterial out- 
flow (runoff), embolization, and coagulation disor- 
ders. 1,3,7 Disorders of coagulation that are known to 
have been associated with cases of acute bypass graft 
failure include deficiencies of antithrombin III or 
protein C and protein S, 8,9 heparin-induced throm- 
bocytopenia (white clot syndrome), l°,ll and anticar- 
diolipin antibodies. 6 In addition, unnamed coagula- 
tion disorders are often suspected in those cases of 
early graft thrombosis in which no technical or ana- 
tomic problem has been identified. 3 
The performance of surgery is lmown to induce a 
homeostatic procoagulant s ate that is manifested by 
increased levels of factor VIII 9;12 and fibrinogen,13,14 
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abnormalities ofplatelet funct ion ,  9,1s'16 and reduced 
endogenous fibrinolytic activity. 17-23 A number of 
previous reports have documented this reduced en- 
dogenous fibrinolysis, which has been termed fi- 
brinolytic shutdown, in the first postoperative week 
after undergoing general surgical procedures, ~7 24 
joint replacement, 2s-28 gynecologic surgery, 12 and 
vascular econstructions. 29-33 Fibrinolytic shutdown 
in the early postoperative period may result in the 
reduced ability to lyse excess or inappropriately- 
formed thrombus and increase the risk of thrombotic 
complications uch as venous thromboembolism, 
myocardial infarction, stroke, and possible graft 
thrombosis. 
In vivo fibrinolytic activity is, at present, best 
reflected by the balance between the activities of 
tissue plasminogen activator (tPA) and its naturally 
occurring inhibitor, plasminogen activator inhibitor 
(PAI-1). tPA cleaves plasminogen to form the active 
enzyme plasmin, which lyses fibrin clots; tPA is inac- 
tivated by formation of a one-to-one stoichiometric 
complex with PAl-1. Recently, it has become possi- 
ble to directly measure the biologic activities of these 
two enzymes, which are primarily responsible for the 
regulation of endogenous fibrinolytic activity. The 
prcsent study was performed to assess endogenous 
fibrinolytic activity at intervals during the postopera- 
tive period after infrainguinal bypass grafting proce- 
dures by direct measurement oftPA and PAI-1 activ- 
ity levels. An attempt was made to characterize the 
precise biologic mechanism of postoperative fibrino- 
lytic shutdown and determine whether educed in 
vivo fibrinolysis may contribute to early graft throm- 
bosis. 
PATIENTS AND METHODS 
The study group consisted of 20 consecutive pa- 
tients who underwent infrainguinal bypass grafting 
procedures at the Baltimore Veterans Affairs Medical 
Center (University of Maryland Medical Systems, 
Baltimore, Md.) from September 1995 to March 
1996. All patients were men, and the mean age of the 
study group was 68 years. The demographic data for 
the study group are shown in Table I; 70% had 
diabetes, 90% had hypertension, and 80% were past 
or present smokers. Infrainguinal reconstruction was 
performed for ischemic ulceration or gangrene in 15 
patients and for rest pain in the remaining five pa- 
tients. The mean preoperative ankle-brachial index 
(ABI) for the study group was 0.33. 
All surgical procedures in this series were per- 
formed with the patient under continuous epidural 
Table I. Study group characteristics 
Characteristic No. Of patients (%) 
Risk factors 
Diabetes mellitus 14 (70) 
Current obacco use 8 (40) 
Former tobacco use 8 (40) 
Hypertension 18 (90) 
Hyperlipidemia 6 (30) 
Indication for surgery 
Ischemic ulceration/gangrene 15 (75) 
Rest pain 5 (25) 
anesthesia using intermittent boluses of 0.5% bupiv- 
acaine. Nineteen bypass procedures were performed 
with autogenous vein; one bypass procedure was 
performed using expanded polytetrafluoroethylene. 
Bypass grafts originated from the common femoral 
artery in 15 patients, the superficial femoral artery in 
one patient, and from the popliteal artery in the 
remaining four patients. The distal anastomosis was 
to the popliteal artery in four patients, to crural 
arteries in 13 patients, and to the dorsalis pedis artery 
in three patients. Intraoperative systemic heparin (70 
U/kg) and low molecular weight dextran (Dextran- 
40, 80 ml/hr) were used in all cases. A continuous 
intravenous infusion of unffactionated heparin at a 
dose of 500 to 800 U/hr  was continued for 72 hours 
after surgery in all patients. 
Endogenous fibrinolytic activity in all patients 
was assessed by serial measurements of serum tPA 
and PAI-1. Baseline blood samples were obtained 
from each patient 2 to 5 days before surgery. Subse- 
quent samples were obtained after completion of the 
surgical procedure and thereafter on postoperative 
days 1, 2, 7, and 30. Antecubital venipuncture was 
performed in each case without tourniquet-induced 
venostasis. Specimens were collected at approxi- 
mately the same time of day to eliminate the known 
diurnal variations in tPA and PAI-1.34 Total protein 
(antigen) levels and biologic activity levels were as- 
sayed for both tPA and PAI-1 at each interval. 
For determination of PAI-1 antigen and activity, 
blood samples were collected in a syringe containing 
modified Files solution (1 ml acid citrate dextrose 
solution, 80 Ixl acetylsalicylic acid solution, 10 txl 
prostaglandin El) to minimize in vitro platelet acti- 
vation (final dilution, 1:5). 35 For determination of 
tPA antigen and activity, blood was first collected 
into 130 mmol/1 sodium citrate anticoagulant (9:1 
volume). The sample for measurement of tPA activ- 
ity was immediately acidified by addition of 0.5 
retool/1 sodium acetate, pH 4.2 (2:1 volume), to 
prevent he ongoing in vitro inactivation of tPA by 
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Table II. Fibrinolytic variables after infrainguinal bypass 
PREOP OP PO 1 PO 2 PO 7 PO 30 
tPA antigen (ng/ml) 8.7 +_ 2.3 14.6 +- 3.0* 7.5 +- 1.6 6.3 + 2.2 7.1 _+ 2.0 3.2 -+ 1.0 
tPA activity ( IU/ml)  2.04 + 0.59 0.79 -+ 0.23* 0.88 -+ 0.24* 1.80 + 0.62 1.89 _+ 0.68 1.07 + 0.30 
PAL1 antigen (ng/ml) 3.2 _+ 1.3 5.1 + 1.6 9.1 _+ 2.1" 7.3 _+ 2.9 5.1 -+ 2.4 2.1 + 0.8 
PAI-1 activity (AU/ml) 20.6 + 1.4 29.6 + 2.2* 27.0 + 2.2* 29.6 _+ 2.4* 22.7 + 0.9 21.5 -+ 2.4 
PREOP, Before surgery; OP, at completion of surgery; PO, postoperative day. 
All values mean _+ SEM. 
*Significant at p < 0.05 compared with preoperative alues. 
complex formation with PAl-1. 36 Samples were 
maintained at 4 ° C until centrifugation at 10,000g 
for 20 minutes. Platelet-poor plasma was stored at 
-80 ° C until assays were performed, tPA and PAI-1 
ant igen levels (ng/ml) were measured using en- 
zyme-linked immunoadsorbent assays. 3s Activity lev- 
els of tPA and PAl-1 were performed using an 
amidolytic methods  All assays were performed in 
duplicate, and interassay variability was determined 
to be less than 5%. tPA activity was expressed in 
international units ( IU/ml) assessed against the 2nd 
International Standard for tPA from the National 
Institute for Biological Standards and ControlY 
PAI-1 activity was expressed in arbitrary units (AU/  
ml); one arbitrary unit of inhibitor is defined as the 
amount hat inhibits one IU of tPA per milliliter of 
plasma. 39 
Data from all patients were pooled at each time 
interval, and mean values for the standard error of 
the mean were calculated for tPA and PAl antigen 
and activity levels. Changes in the serum levels oftPA 
and PAl-1 at different time intervals were compared 
using Student's ttest, and a p value less than 0.05 was 
used to determine statistical significance. This protocol 
was approved by the Institutional Review Board of the 
University of Maryland, and informed consent was 
obtained from all subjects before their participation. 
RESULTS 
Infrainguinal bypass grafting outcome. Intra- 
operative completion arteriograms were obtained af- 
ter each bypass grafting procedure in this series and 
demonstrated a satisfactory technical result with ade- 
quate arterial outflow. Distal arterial perfusion was 
significantly improved in these limbs, with a mean 
postoperative ABI of 0.90 in the study group. No 
graft occlusions occurred during the first 30 days 
after surgery. No patient in the study had any other 
significant atherothrombotic event, such as myocar- 
dial infarction, stroke, or venous thrombosis, during 
the early postoperative period. No major amputa- 
tions were required, and all of the study participants 
were discharged ambulatory. 
tPA antigen and activity. The values for tPA 
antigen and activity are listed in Table II. The mean 
preoperative tPA antigen level was 8.71 + 2.30 rig/ 
ml. Antigen levels increased significantly to 14.59 + 
3.01 ng/ml  (p = 0.037) immediately after bypass 
surgery (Fig. 1). Serum tPA antigen levels returned 
to baseline preoperative l vels by postoperative day 
one (7.53 + 1.63 ng/ml;  p = 0.72 compared with 
preoperative l vels) and remained statistically un- 
changed throughout the remainder of the study pe- 
riod. The mean preoperative tPA activity level was 
2.04 + 0.59 IU/ml.  A significant decrease in tPA 
activity (0.79 + 0.23 IU/ml;  p = 0.046) was ob- 
served immediately after surgery, and tPA activity 
remained at a significantly reduced level on postop- 
erative day one (Fig. 2). Activity levels for tPA had 
returned to baseline on postoperative day two and 
did not change significantly thereafter during the 
study period. 
PAI-1 antigen and activity. The values for 
PAL1 antigen and activity levels at each interval in 
the study are listed in Table II. The mean serum 
PM-1 antigen level was 3.24 + 1.33 ng/ml  before 
surgery and increased to 5.06 + 1.62 ng/ml  at 
completion of surgery (p = 0.32). A further increase 
in PAI-1 antigen to 9.08 + 2.06 ng/ml  was ob- 
served on postoperative day one, which was signifi- 
cantly higher than preoperative l vels (p = 0.03). 
Thereafter, PAl-1 antigen levels returned to baseline 
by the end of the first postoperative week. Mean 
serum PM-1 activity was 20.6 + 1.4 AU/ml  before 
surgery, and a significant increase in mean serum 
PAI-1 activity was observed at the completion of 
surgery (29.6 + 2.2 AU/ml;  p = 0.002; Fig. 2). 
Serum PM-1 activity levels remained significantly 
elevated on postoperative days one and two com- 
pared with preoperative l vels. Serum PAl-1 activity 
levels returned to baseline by postoperative day seven 
and remained unchanged at postoperative day 30. 
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Fig. 1. tPA activity (IU/ml) and antigen (ng/ml) before surgery (PREOP), at completion of 
surgery (OP), and on postoperative (PO) days 1, 2, 7, and 30. 
DISCUSSION 
Patients in the present study exhibited defective 
endogenous fibrinolytic activity in the immediate 
postoperative period after undergoing infrainguinal 
bypass grafting procedures for severe limb ischemia. 
Reduced fibrinolytic activity in these cases was char- 
acterized by a combination of significantly reduced 
tPA activity, which was observed from the completion 
of surgery through the first postoperative day, and by 
increased activity of its inhibitor PM-1, which was sig- 
nificantly elevated from the time of surgery through 
postoperative day two. Fibfinolytic activity, as reflected 
by changes in tPA and PM activities, returned to base- 
line levels before the end of the first postoperative week. 
Previous studies have demonstrated reduced 
postoperative fibrinolytic activity in patients who un- 
dergo general surgical procedures, 1724 joint replace- 
ment, 25-28 gynecologic surgery, 12 surgery for major 
trauma, 23 and vascular reconstructions. 29-33 These 
studies often used euglobulin clot lysis times 
(ECLTs, a global measurement of clot lysis) for 
quantification of fibrinolytic activity. Currently, 
ECLTs are used infrequently because specific assays 
of the factors that govern endogenous fibrinolysis 
such as tPA and PAI-1 are now available. 4° Kluft et 
al. 23 studied patients who underwent general surgical 
procedures and observed that tPA activity decreased 
to essentially undetectable l vels on postoperative 
day one and returned to their baseline levels by the 
third day after surgery. They also observed that the 
activity of a fast-acting tPA inhibitor (which is now 
lmown to be PAl-1) was also significantly increased. 
These mechanisms of postoperative fibrinolytic shut- 
down are essentially identical to those that we ob- 
served in the patients in this study. 
Disorders of the host coagulation system after 
arterial bypass grafting may cause bypass graft throm- 
bosis. Stept et al.3 reported that 14% of early in- 
frainguinal graft failures were caused by identifiable 
hypercoagulable states uch as antithrombin III defi- 
ciency, and other reports have noted early graft oc- 
clusion as a result of protein C and S deficiencies, 
heparin-induced thrombocytopenia, and anticardio- 
lipin antibodies. 6,8- ~ 1 McDaniel et al.9 reported that a 
hypercoagulable r sponse developed in the first 72 
hours after infrainguinal bypass grafting that was 
marked by increased platelet reactivity, increased fac- 
tor VIII levels, and reduced levels of antithrombin 
III, but no significant decrease in postoperative fi-
brinolytic activity was observed in their patients. 
Earnshaw et al.31 reported that reduced postopera- 
tive fibrinolytic activity was a significant risk factor for 
early thrombosis of femoropopliteal bypass grafts. 
The mechanism of fibrinolytic shutdown after 
aortic surgery was studied by Gomez et al., 32 who 
observed that this mechanism was mediated by a 
significant increase in PAI-1 levels. Rosenfeld et al. 29 
reported significantly higher PAI-1 activity levels in 
patients who had thrombotic complications (pre- 
dominantly graft thrombosis) after lower extremity 
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Fig. 2. tPA (IU/ml) and PAI-I (AU/ml) activities before surgery (PREOP), at completion of 
surgery (OP), and on postoperative (PO) days 1, 2, 7, and 30. 
revascularization procedures. The present study also 
observed significantly increased PM-1 activity levels 
immediately after infrainguinal bypass grafting and 
on postoperative days one and two. This was accom- 
panied in our patients by a significant reduction in 
tPA activity after surgery and on postoperative day 
one, a finding not previously reported in vascular 
surgery patients. No thrombotic omplications oc- 
curred in the patients in this series, but empiric anti- 
thrombotic therapy (heparin) was used in all our 
cases .  
Surgical procedures performed with the patient 
under epidural anesthesia have been reported to have 
reduced postoperative hypercoagulability and fewer 
thrombotic complications compared with similar 
procedures performed with the patient under general 
anesthesia) 2,25,29,3°,33,41,42 Reduced factor VIII lev- 
els were observed in patients after gynecologic proce- 
dures ~2 and total joint replacements 2a,42 when epi- 
dural anesthesia was used compared with procedures 
performed with the patient under general anesthesia. 
A reduced level of fibrinolytic inhibitor was found in 
patients who underwent total hip replacement under 
epidural anesthesia, suggesting enhanced fibrinolytic 
activity in these cases, 25 and this has been associated 
with a lower incidence of venous thromboembolic 
complications. 42 In two separate reports of a similar 
patient group, Rosenfeld et al .  29 and Perler et al?0 
noted a significant increase in postoperative PAI-1 
activity levels in patients who underwent lower limb 
revascularization u der general anesthesia. However, 
patients who underwent infrainguinal bypass grafting 
procedures under epidural anesthesia did not have 
significant postoperative increases in PAI-1 activity. 
Thrombotic omplications occurred more frequently 
in patients who had elevated PAI-1 activity, and thus 
patients who had epidural anesthesia had signifi- 
cantly fewer graft thromboses. 
All patients in the present study underwent in- 
frainguinal bypass grafting under epidural anesthesia, 
but significant postoperative increases in PAL 1 activ- 
ities were seen despite the use of this anesthetic 
technique. There was a higher incidence of diabetes 
mellims in the patients in this study (70%) compared 
with the above reports (35% to 39%), and PAI-I 
levels are known to bc higher in diabetic patients. 43 
The severity of atherosclerosis may also have been 
greater in our patients (bypass procedures were per- 
formed for clandication alone in 16% of patients in 
the report of Perler et al?0 but in none of our 
patients), and PM-1 activity levels are lmown to be 
higher in patients with more severe athcrosclerosis.44 
The preoperative l vels of PAl-1 reported by Rosen- 
reid et al.29 (13.6 AU/ml) were similar to those 
observed in normal volunteers in our laboratory 
(12.5 AU/ml)  but were lower than preoperative 
PAI-1 levels in the patients in the current study (20.6 
AU/ml,  Table II). Overall, our patient population 
may have been more prone to further postoperative 
fibrinolytic shutdown and thus did not demonstrate 
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the potential protective ffect o f  epidural anesthesia. 
Regardless of  the anesthetic technique, it appears 
that a pattern of  significantly elevated PAI-1 in the 
perioperative period after infrainguinal bypass graft- 
ing signals a clinically relevant reduction in endog- 
enous fibrinolytic activity and a significant hy- 
percoagulable state. It  is  possible that thrombot ic  
complications were avoided in the present study by 
the routine postoperative use of  systemic heparin 
therapy. 
Reduced postoperative fibrinolytic activity in this 
study was characterized by an increase in PAI-1 activ- 
ity and a significant decrease in tPA activity. How-  
ever, tPA antigen ,levels increased significantly in the 
first 24 hours after the bypass procedure. This seem- 
ingly paradoxical elevation of  the tPA antigen level 
does not indicate increased fibrinolytic activity. Pre- 
vious studies have observed that elevated tPA antigen 
levels may occur in association with reduced in vivo 
fibrinolysis. 23 The assay for tPA antigen measures 
both the free, active cnzyme and the biologically 
inactive tPA/PA I -1  complex. 3s-37 Increased tPA an- 
tigen levels seen in this study probably reflect in- 
creased amounts of  complex (perhaps generated by 
significantly increased PA Id  levels), which reflects a 
tendency toward coagulation rather than enhanced 
fibrinolysis. 4s An increased risk o f  athcrothrombotic 
events such as myocardial infarction have been asso- 
ciated with elevated tPA antigen levels. 46 
Preoperative PAI-1 activity levels in our study 
patients were elevated compared with values previ- 
ously reported for normal age and sex-matched 
control subjects, 44,4s,47 but were similar to those ob- 
served in patients with peripheral arterial dis- 
ease. 44,47,48 Elevated PAI-1 activity levels have been 
associated with coronary artery disease 4s and 
stroke, 49 and are a risk factor for recurrent myocar- 
dial infarction. 4s There is increasing evidence that 
the formation and progression of  atherosclerotic 
plaque and the occurrence of  clinical events that 
result from atherosclcrosis are associated with im- 
paired fibrinolytic activity. This study provides addi- 
tional evidence that advanced degrees of  peripheral 
arterial disease are also associated with elevated 
PAI-1 activity and defective ndogenous fibrinolysis~ 
The only currently available method for modifying 
endogenous fibrinolytic activity directly is the use of  
exogenous thrombolyt ic agents, which has been as- 
sociated with unacceptably high complication rates 
in the immediate postoperative period, s° Postopera- 
tive heparin anticoagulation may be a practical alter- 
native to treat any hypercoagulable state that occurs 
after surgery, but heparin itself has no direct effect on 
fibrinolysis, sl Further study in larger groups of  pa- 
tients who require surgical treatment will be nec- 
essary to clarify the effects of  associated medical 
conditions, anesthetic techniques, and alternative an- 
t i thrombotic strategies on the development and clin- 
ical course of  fibrinolytic shutdown in these cases. 
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DISCUSSION 
Dr. Mark A. Mattos (Springfield, 111.). Dr. Killewich 
and her fellow authors are to be congratulated for present- 
ing data today that have really increased our knowledge 
and understanding of the complex interactions and rela- 
tionships of the specific factors that define the in vivo 
fibrinolytic activity, namely tPA and its naturally occurring 
inhibitor, PAI- 1. They have attempted to show the partic- 
ular changes that Occur in these factors in a very specific 
subgroup of patients, namely those with vascular disease, 
adult male Veterans Affairs patients with diabetes and hy- 
pertension and who smoke. The patients also underwent 
infrainguinal bypass grafting procedures under epidural 
anesthesia. The data show convincingly that the fibrinolytic 
shutdown does occur in the perioperative period and ap- 
pears to last, in terms of the increased activity of PAI, out 
to 7 days. The authors tate that although eparin does not 
affect his reduction of flbrinolysis, it appears to be associ- 
ated with a reduced incidence of early graft thrombosis, 
and they suggest i s use as a practical alternative to prevent: 
ing early graft thrombosis. I have several questions involv- 
ing the study. 
First, I would like to know whether fibrinolytic activity 
increases out to 7 days, and does it make any sense to just 
maintain the heparin for 72 hours, or does it affect it at all? 
Certainly, by your study the presence of heparin did not 
affect whether flbrinolytic shutdown occurred or not. 
My second question, why only 72 hours for your hep- 
arin? Was 24 hours just as good? Can we make any con- 
crete conclusions about this in terms ofgiving heparin or 
not based on Only 20 patients? Again this is very select. It 
does not include women, and I would like to know what 
your comment is in terms of the involvement of women 
and 'what heir activity would be. 
Third, at Southern Illinois University, we tend to have 
a bit of a problem when we give postoperative h parin after 
long leg bypass procedures and have had several hemato- 
mas and have basically stopped using heparin in the post- 
operative period except in those patients in whom we 
perform a very, very distal bypass procedure that goes 
down to the ankle with a very, very limited outflow. 
My other question has to do with the type of opera- 
tions that were performed. Some literature would state that 
there is a greater fibrinolytic activity in those people who 
undergo in situ bypass procedures versus those who un- 
dergo reversed saphenous vein bypass procedures. Can you 
give us a break-down in the 19 patients who underwent 
reversed vein bypass procedures between saphenous vein 
or in situ, as to whether there was any difference in their 
levels? 
Dr. Lois A. Killewich. I think the first two questions 
were with regard to the length of time that we used 
heparin. Basically, there is a certain amount of arbitrariness 
in the length of time that we chose to use the heparin. 
From the data, it appears that the flbrinolytic shutdown 
lasts through postoperative day two, and previous literature 
studies would suggest hat by postoperative day three this 
fibrinolytic shutdown is for the most part resolved, which is 
why we chose the 72-hour period to use the heparin. 
I can't defend my data in terms of the fact that there are 
no women in my study. My study was done at the Veterans 
Affairs Hospital, and certainly in the future a good thing to do 
would be to enlarge the study to include women. 
In terms of the hematomas, we have had very good 
luck with having few hemorrhagic complications, includ- 
ing hematomas or other types of hemorrhagic problems, 
using 500 U of heparin per hour. Again, this is a very 
arbitrary dose that we have chosen, but we have found that 
if we use this dose, which we call low-dose heparin, we get 
very few hemorrhagic complications and we seem to still 
have the protective ffect of heparin in terms of maintain- 
ing bypass graft patency. 
Finally, in terms of the breakdown of these bypass 
grafts, they were about 50% in situ and about 50% reversed 
vein bypass procedures. I did not go over the data in great 
detail, but the popliteal-to-tibial bypass procedures were all 
performed by removing the vein and reversing it. 
